Making ibuprofen faster for 20 years. Faster processes: Ibuprofen DC 85 reduces production time and costs. Faster acting: Ibuprofen Sodium & Racemic Ibuprofen Lysinate take effect faster than conventional ibuprofen.
20 years of making ibuprofen faster
Faster processes: Ibuprofen DC 85 helps to decrease production time and to reduce costs. Designed specifically for direct compression into tablets, Ibuprofen DC 85 offers a number of benefits compared to conventional formulations. A common challenge when processing ibuprofen is the relatively low melting point: the API gradually starts to melt during processing and can stick to the machinery – meaning production must be stopped to clean the tablet punches. The active ingredient in Ibuprofen DC 85, in contrast, is coated with a layer of nanomaterial, which provides protection during manufacturing. The result is reliable fault-free tableting production with higher output rates. Furthermore, as expensive wet granulation and compaction processing steps are no longer necessary, our customers can lower production costs.
Speed of action: Ibuprofen Sodium & Racemic Ibuprofen Lysinate (RIBL) dissolve faster than conventional ibuprofen. This means they provide more rapid and effective pain relief during the first hour – so patients are back to full speed in no time.
BASF, the world leader in generic APIs, has been deploying the industry’s most eco-efficient ibuprofen manufacturing process for over 20 years.
BASF Pharma Ingredients and Services
http://www.pharma-ingredients.basf.com/ibuprofen/Home.aspxpharma-ingredients@basf.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.